A brain alarm system misfires as we age
In healthy brains, an alarm system stands guard against invaders. In aging brains, that same system fires continuously, without any real threat. The resulting damage is linked to diseases like Alzheimer’s and Parkinson’s.
The system in question is a molecular circuit known as cGAS-STING. Under normal conditions, it detects double-stranded DNA in places where it should not be, such as outside the cell nucleus or outside the mitochondria. That is a sign of bacterial or viral infection, and the system responds with an inflammatory signal. The study describes how this circuit becomes chronically overactive in aged brain cells, producing persistent low-grade inflammation.
The explanation lies in the mitochondria: the small structures in cells that produce energy. As we age, mitochondria become damaged and fragments of mitochondrial DNA escape into the surrounding cell fluid. The cGAS protein recognises these fragments as danger signals and activates STING, a central hub for inflammatory responses. In brain cells, including microglia (the brain’s resident immune cells), this leads to continuous inflammation that promotes tissue damage.
Why this matters for brain aging
Chronic inflammation in the brain is a hallmark of neurodegeneration. Earlier research already pointed to microglia becoming increasingly inflammatory with age. The cGAS-STING circuit offers a possible explanation for why: damaged mitochondria leak DNA fragments, the system reads these as threats, and the result is a sustained inflammatory state.
This makes addressing mitochondrial damage in the aging brain particularly relevant. It is not just a matter of declining energy production; it is also about preventing DNA leakage that keeps the brain’s immune system on high alert.
What this means for research
Researchers now view cGAS-STING as a potential target for treatments against neurodegenerative disease. Compounds that suppress this signalling pathway are already being studied in other contexts, such as autoimmune conditions. Whether they could also protect against Alzheimer’s or Parkinson’s remains an open question. The findings in this review are preliminary and call for targeted follow-up work in specific disease models.